Key Points
- CEO Matthew Kapusta sold 12,378 shares on Feb. 25 at an average price of $23.86 for about $295,339, reducing his stake by 1.90% to 639,076 shares.
- Regulatory and legal pressure is weighing on the stock after critical FDA commentary about a rejected rare‑disease therapy prompted a selloff and multiple securities‑class action filings and law‑firm notices.
- The stock trades with a market cap of roughly $974M and a 52‑week range of $7.76–$71.50, while analysts show a mixed view (10 Buys, 4 Holds, 1 Sell) and an average target of about $58.33.
uniQure N.V. (NASDAQ:QURE - Get Free Report) CFO Christian Klemt sold 6,217 shares of the business's stock in a transaction on Wednesday, February 25th. The stock was sold at an average price of $23.86, for a total value of $148,337.62. Following the completion of the sale, the chief financial officer directly owned 211,513 shares in the company, valued at $5,046,700.18. This represents a 2.86% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link.
uniQure Trading Down 8.6%
Shares of QURE stock opened at $15.63 on Friday. The stock has a 50-day simple moving average of $23.46 and a 200 day simple moving average of $29.59. The stock has a market capitalization of $973.59 million, a P/E ratio of -3.56 and a beta of 0.66. uniQure N.V. has a fifty-two week low of $7.76 and a fifty-two week high of $71.50. The company has a quick ratio of 7.12, a current ratio of 7.12 and a debt-to-equity ratio of 0.23.
Institutional Investors Weigh In On uniQure
Institutional investors have recently bought and sold shares of the business. Private Trust Co. NA acquired a new position in shares of uniQure in the 3rd quarter valued at about $28,000. Torren Management LLC acquired a new stake in shares of uniQure during the fourth quarter worth approximately $28,000. Jones Financial Companies Lllp grew its position in uniQure by 509.0% during the third quarter. Jones Financial Companies Lllp now owns 609 shares of the biotechnology company's stock valued at $33,000 after purchasing an additional 509 shares in the last quarter. IFP Advisors Inc acquired a new position in uniQure in the 4th quarter valued at approximately $48,000. Finally, Smartleaf Asset Management LLC purchased a new stake in uniQure in the 4th quarter worth approximately $48,000. 78.83% of the stock is currently owned by institutional investors and hedge funds.
Trending Headlines about uniQure
Here are the key news stories impacting uniQure this week:
- Positive Sentiment: Unusual bullish options flow — heavy call buying (24,345 calls, ~181% above typical volume) suggests some traders are speculating on a near‑term rebound or event‑driven move.
- Negative Sentiment: Fresh FDA controversy: coverage highlights critical comments from FDA leadership about uniQure’s rejected rare‑disease therapy, which markets see as increasing regulatory risk for the program. uniQure: Shares Tumble On Fresh FDA Controversy - What Investors Should Know
- Negative Sentiment: FDA commissioner comments drew broad media coverage and were cited as the main driver of the selloff, amplifying short‑term downside as investors reassess approval odds. UniQure plummets as FDA's Marty Makary disparages rejected rare disease drug
- Negative Sentiment: Multiple securities‑class action filings and firm notices: several law firms are publicizing suits or seeking lead plaintiffs for alleged misstatements during a specified class period — increasing legal and reputational risk and likely weighing on sentiment. Representative notices: DJS Law Group. uniQure N.V. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - QURE
- Negative Sentiment: Broad wave of law‑firm alerts and reminder notices (Rosen, Pomerantz, Faruqi, Robbins, Berger Montague, etc.) highlights that litigation momentum is building and that April 13, 2026 lead‑plaintiff deadlines are approaching — an added near‑term overhang. Example: Rosen Law Firm reminder. ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages uniQure N.V. Investors to Secure Counsel Before Important Deadline in Securities Class Action - QURE
- Negative Sentiment: Market reaction summaries: analyst/news pieces attribute a large intraday drop to the FDA remarks and resulting uncertainty, reinforcing negative sentiment. Why Is uniQure Stock Down 30% Today?
Analyst Upgrades and Downgrades
QURE has been the subject of several recent research reports. Stifel Nicolaus cut their target price on shares of uniQure from $50.00 to $40.00 and set a "buy" rating for the company in a research note on Thursday, December 11th. Mizuho cut their price objective on uniQure from $60.00 to $33.00 and set an "outperform" rating for the company in a research report on Monday, December 8th. Leerink Partners reduced their price objective on uniQure from $68.00 to $60.00 and set an "outperform" rating for the company in a research note on Monday, November 10th. Barclays assumed coverage on uniQure in a research report on Tuesday, January 27th. They set an "equal weight" rating and a $31.00 target price on the stock. Finally, Wells Fargo & Company reduced their target price on uniQure from $80.00 to $60.00 and set an "overweight" rating for the company in a report on Wednesday, November 12th. Ten research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, uniQure presently has a consensus rating of "Moderate Buy" and a consensus price target of $58.33.
View Our Latest Stock Analysis on uniQure
uniQure Company Profile
(
Get Free Report)
uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.
Beyond hemophilia B, uniQure's pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington's disease, and Parkinson's disease.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
